Etamsylate is a synthetic antihemorrhagic (hemostatic) agent primarily used to reduce bleeding by enhancing the initial phase of hemostasis, specifically by promoting endothelial-platelet interactions . Unlike many hemostatics, etamsylate does not cause vasoconstriction , nor does it affect the coagulation cascade or fibrinolysis.
Mechanism of Action
- Primary action : Improves platelet adhesiveness to damaged endothelium, promoting platelet plug formation.
- Effect on capillaries : Increases capillary resistance and reduces capillary permeability, which decreases bleeding time and blood loss.
- Does NOT :
- Affect fibrin mesh breakdown (fibrinolysis).
- Modify plasma coagulation factors.
- Induce vasoconstriction.
Pharmacokinetics
- Crosses the placental barrier , resulting in similar drug concentrations in maternal and fetal blood.
- Onset of action: 1 to 5 minutes after parenteral administration.
- Excretion: Mostly unchanged via biliary, urinary, and intestinal routes.
- Blood levels: Approximately 6.5%–11.5% remains after 1 hour post administration.
- No teratogenic effects reported in multi-generational animal studies.
Indications
Internal Medicine
- Prevention and treatment of capillary hemorrhages of various origins.
- Conditions with bleeding symptoms:
- Hematuria (blood in urine)
- Hematemesis (vomiting blood)
- Melena (black tarry stools from GI bleeding)
- Metrorrhagia (abnormal uterine bleeding)
- Primary or IUD-related metrorrhagia
- Hemorrhagic gingivitis
Surgery
- Prevention and management of postoperative bleeding (oozing), especially in highly vascularized tissues.
- Specific surgical fields:
- Ear, Nose, and Throat (ENT)
- Urology
- Ophthalmology
- Odontostomatology (dental surgery)
- Plastic and reconstructive surgery
Obstetrics and Gynecology
- Used to control bleeding during gynecological and obstetric surgeries.
Pediatrics
- Prevention of hemorrhages in premature or preterm neonates.
Dosage and Administration
Adults
- Preoperative : 1–2 ampoules (IV/IM) 1 hour before surgery.
- Perioperative : 1–2 ampoules (IV), repeat if necessary.
- Postoperative : 1–2 ampoules (IV/IM) every 4–6 hours as long as bleeding risk persists.
- Emergency bleeding : 1–2 ampoules every 4–6 hours, titrated to severity.
Note : IV doses should ideally be diluted 1:2 with dextrose or saline.
Local Use
- Swab soaked with ampoule content applied directly to bleeding site or tooth socket post-extraction. May be repeated as needed, often combined with systemic administration.
Pediatrics
- Half of the adult dose.
Neonates
- 10 mg/kg body weight (approx. 0.1 mL or 12.5 mg) IM within 2 hours after birth, then every 6 hours for 4 days.
Contraindications and Precautions
- Avoid use during the first trimester of pregnancy due to insufficient safety data.
- Use cautiously in patients with known hypersensitivity to etamsylate.
Adverse Effects
- Generally well tolerated.
- Rare side effects may include:
- Nausea and vomiting
- Headache
- Skin rash
- No significant allergic or serological reactions reported.
High-Yield Notes
- Etamsylate promotes hemostasis by enhancing platelet-endothelium interaction without affecting coagulation factors or fibrinolysis.
- Does not cause vasoconstriction , distinguishing it from other hemostatic agents like vasopressin.
- Crosses placenta, so fetal exposure occurs; however, no teratogenicity seen in animal studies.
- Useful for bleeding in various clinical settings: internal medicine (capillary hemorrhages), surgery (post-op bleeding), obstetrics (metrorrhagia), and neonatology (preterm hemorrhages).
- Administered parenterally (IV/IM); local topical use possible.
- Avoid first trimester of pregnancy.
- Side effects are rare and mild.
